Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Receivables: 2021-2025

Historic Receivables for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Sep 2025 value amounting to $107.1 million.

  • Mirum Pharmaceuticals' Receivables rose 56.33% to $107.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $388.1 million, marking a year-over-year increase of 54.05%. This contributed to the annual value of $78.3 million for FY2024, which is 15.18% up from last year.
  • Mirum Pharmaceuticals' Receivables amounted to $107.1 million in Q3 2025, which was up 0.28% from $106.8 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Receivables peaked at $107.1 million during Q3 2025, and registered a low of $400,000 during Q3 2021.
  • Over the past 3 years, Mirum Pharmaceuticals' median Receivables value was $68.0 million (recorded in 2023), while the average stood at $68.0 million.
  • Data for Mirum Pharmaceuticals' Receivables shows a peak YoY spiked of 3,984.25% (in 2022) over the last 5 years.
  • Over the past 5 years, Mirum Pharmaceuticals' Receivables (Quarterly) stood at $3.3 million in 2021, then spiked by 634.44% to $24.0 million in 2022, then soared by 183.27% to $68.0 million in 2023, then grew by 15.18% to $78.3 million in 2024, then spiked by 56.33% to $107.1 million in 2025.
  • Its last three reported values are $107.1 million in Q3 2025, $106.8 million for Q2 2025, and $95.9 million during Q1 2025.